GeoVax Labs, Inc. (OTCBB: GOVX) is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using our novel Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform technology. Our platform supports production of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine. Producing VLPs in the person being vaccinated mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent and control the target infection should it appear.
Our current development programs are focused on vaccines against Human Immunodeficiency Virus (HIV), Hemorrhagic Fever viruses such as Ebola (Zaire, Sudan), Marburg and Lassa, Malaria and Zika virus. We have also initiated programs to develop a vaccine to treat chronic Hepatitis B (HBV) infection and to apply our MVA-VLP vector technology to cancer immunotherapy (immuno-oncology). We believe our technology and vaccine development expertise is well-suited for a wide variety of human diseases for which there is an unmet medical need, and we intend to pursue expansion of our product pipeline.
Our hemorrhagic fever vaccine program was initiated during 2014 in response to the Ebola epidemic in western Africa and with the goal of developing second generation monovalent and multivalent vaccines capable of preventing or containing future outbreaks of major hemorrhagic fever viruses indigenous to Africa. Our initial preclinical studies in rodents and nonhuman primates for our first vaccine candidate (Ebola-Zaire virus) have shown 100% protection against death after a single dose.
Our most advanced vaccines under development are designed to function against the clade B subtype of the HIV virus that is prevalent in the Americas and Western Europe. Our preventive clade B HIV vaccine has successfully completed Phase 2a human clinical testing has entered a follow-on clinical trial in 2017. Our clade B vaccine has shown outstanding safety and excellent, highly reproducible immunogenicity. We are extending our HIV vaccine effort to the most common virus subtype affecting the developing world, clade C. We also are investigating our HIV vaccines for their potential to contribute to combination therapies leading to a cure for HIV infections.
Our vaccine technology was developed in collaboration with researchers at Emory University, the NIH, and the CDC. The technology is exclusively licensed to us from Emory University. We also have nonexclusive licenses to certain patents owned by the NIH. Our hemorrhagic fever vaccines have been developed with technology licensed from, and in collaboration with, the NIH. Our immuno-oncology program is being developed pursuant to a research collaboration with the University of Pittsburgh. Our Zika vaccine program is in collaboration with the CDC. Our HBV therapeutic program is in collaboration with Georgia State University and our malaria vaccine is being developed in collaboration with Burnet Institute in Australia.
Our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants awarded directly to us, in kind support in terms of animal experiments, as well as indirect support for the conduct of our human clinical trials. All of the human clinical trials of our preventative vaccines to date have been conducted by the HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH).